Viridian Therapeutics, Inc. (VRDN) is a pioneering biopharmaceutical firm focused on developing transformative new treatments using its innovative and groundbreaking approaches. The company is committed to devising strategies to leverage understudied areas of biology to discover drugs that confront serious diseases with substantial unmet medical needs. Based in Boulder, Colorado, it is dedicated to progressing its portfolio through rigorous clinical development toward commercial viability.
Viridian Therapeutics was formerly known as miRagen Therapeutics, Inc., a company specializing in the discovery and development of RNA-targeted therapies. In January 2021, they underwent a corporate rebrand to Viridian Therapeutics and shifted their strategic focus in a bid to explore and exploit different areas of drug development with greater potential. The company name, Viridian, reflects its commitment to sustainable, evergreen solutions in the field of drug discovery and development.
Today, Viridian Therapeutics' primary drug candidate is VRDN-001, an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, which has potential use in treating patients with thyroid eye disease (TED). The company believes that VRDN-001 has the potential to be the most effective IGF-1R inhibitor for TED, based on its potent and affine binding profile for the receptor. The company believes VRDN-001 will provide a differentiated and improved treatment option for patients with TED because IGF-1R is believed to play a central role in the pathogenesis of TED.
Viridian Therapeutics also boasts a unique microRNA platform. In the fields of oncology, hematology, and fibrotic diseases, Viridian's portfolio includes MRG-110, an anti-miR-92 microRNA inhibitor in a clinical trial stage, and MRG-229, an anti-miR-29 molecule in the preclinical study phase.
Viridian Therapeutics adheres to a collaborative and partnership-driven approach in pursuit of its mission. The company continually studies, explores, and investigates various pathways and targets to develop therapies that will ultimately save and improve patient lives. By joining forces with scientific and industry partners and leveraging patient and physician insights, Viridian aims to rethink and reinvigorate the conventional processes of drug discovery, development, and delivery.
In summary, Viridian Therapeutics, Inc. is a compelling player in the biopharmaceutical sector, consistently working to create impactful and sustainable changes within the realm of drug development and patient care. Their ongoing commitment to delivering high-quality and potentially life-saving treatments to patients sets them apart in the complex and rapidly evolving world of biopharmaceuticals. Their promising pipeline and progressive research strategies make Viridian Therapeutics a name to watch in the industry for years to come.